Engineered Natural Killer Cells With Timed Safety Switches
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Natural killer (NK) cells have a limited lifespan and persistence in vivo, which poses a challenge for their clinical application in cancer therapy, necessitating approaches for prolonged survival.
Innovation Solution
Engineering NK cells with chimeric polypeptides comprising ligand binding regions and signaling regions, such as MyD88 polypeptides, CD40 cytoplasmic polypeptides, and IL-15, along with chimeric antigen receptors (CARs) and pro-apoptotic polypeptides, to enhance their survival and targeting capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NK cells are used for cancer therapy, then they can directly inject toxic proteins into target cells and produce cytotoxicity, but their lifespan is limited (estimated half-life 14 days, persistence in vivo around one month)
Solution Approach 1:
The patent introduces a safety switch mechanism that is activated only after the NK cells have persisted in the tumor microenvironment for a predetermined period (e.g., 21 days). This preliminary timing mechanism ensures that the pro-apoptotic polypeptide is expressed and becomes active only after the NK cells have had sufficient time to exert their cytotoxic effect, thereby preventing premature termination of their function while maintaining safety controls.
Solution Approach 2:
The patent employs dynamic control of the pro-apoptotic polypeptide expression through a safety switch mechanism that responds to temporal conditions. The system transitions from an inactive state during the initial NK cell persistence phase to an active pro-apoptotic state after the predetermined time period, allowing flexible control over when cell termination occurs based on the actual duration of NK cell presence in the tumor.
2Reliability
If NK cells are engineered with chimeric polypeptides and CARs to enhance targeting, then their specificity and cytotoxicity against cancer cells improve, but the complexity of the cellular machinery increases
Solution Approach 1:
The patent divides the NK cell engineering into distinct functional modules: (1) chimeric antigen receptors (CARs) for tumor targeting, (2) chimeric polypeptides with ligand binding and signaling regions for activation, (3) pro-apoptotic polypeptides for safety control, and (4) safety switch mechanisms for temporal regulation. This segmentation allows each component to be independently designed, optimized, and controlled, reducing the overall complexity by making the system modular and easier to manage.
Solution Approach 2:
The patent introduces intermediary proteins such as the safety switch mechanism and pro-apoptotic polypeptides that mediate between the NK cell's cytotoxic function and the desired safety control. These intermediaries act as regulatory bridges, allowing the complex NK cell system to be controlled externally through temporal conditions without requiring direct manipulation of the core cytotoxic machinery, thereby simplifying the control architecture.
Data Source
AI summary
The technology relates generally to the field of immunology and relates in part to compositions and methods for growing and storing modified natural killer cells, including for example, conditional chemical regulation of natural killer cell function. The technology further relates to pharmaceutical compositions and treatment of subjects using modified natural killer cells.